HerzigRon.jpg (Original)

Ron Herzig, PhD


As a consulting principal on Sg2’s Life Sciences team, Ron leads strategic engagements with the pharmaceutical industry (pharma), medical device companies and distributors to provide market insights and direction on their strategically important growth areas. He brings over 2 decades of international experience working in strategic leadership roles driving competitive market success across product and service lines. His career spans the discovery, product development and marketed products business segments in biotechnology, pharma and medical device, which has allowed him to have a broad and deep perspective on the complexity involved in achieving product-market fit, penetration and share. Ron is passionate about bringing together his scientific rigor and business acumen to solve strategic challenges for Sg2 clients.

Ron moved away from the bench early in his career to profit and loss ownership roles for products and services companies like Millipore and Thermo Fisher targeting the drug discovery market. He is as familiar with smaller start-up companies as he is with very large multinationals. As the program development leader for a late-stage start-up, Ron was instrumental in the development of a next-generation drug eluting coronary stent and the subsequent acquisition of the company by Medtronic. Additionally, he served as the chief operating officer of the only internationally based research center for the Smithsonian Institution. Upon returning to the US, Ron joined a strategic and innovation consulting firm focused on helping Fortune 100 companies in the life sciences industry realize major new growth. Finally, prior to joining Sg2, Ron was the VP of BioPharma Commercial Strategy for PPD, carrying forward strategic growth initiatives across the enterprise.

Ron confirmed his passion for the life sciences while pursuing his BS in biology at the University of California, Los Angeles, where he also supported research on the molecular etiology of HIV and leukemias in the Division of Hematology and Oncology. He subsequently earned his PhD from Northwestern University in molecular and cellular biology studying the molecular basis of metabolism as it relates to disease progression. Early in Ron’s career, he co-invented an innovative gene therapy technology that today is bringing hope in the clinic to individuals suffering from conditions such as neuroblastoma.